Chemed (NYSE:CHE) Stock: Insider Kevin Mcnamara Sells 2,000 Shares

Key Points

• CEO Kevin Mcnamara sold 2,000 Chemed shares at an average price of $513.45, generating approximately $1.03 million. His remaining direct ownership totaled 66,418 shares valued at roughly $34.1 million.
• Chemed’s shares traded at $505.77, down $6.28, while the company reported quarterly EPS of $6.06—beating estimates—and revenue of $673.25 million, up 8.8% year over year.
• The company raised its quarterly dividend to $0.70, or $2.80 annually, while analysts maintained a consensus “Hold” rating with a $554.60 price target; institutional investors own 95.85% of the stock.

Chemed Corporation (NYSE:CHE - Get Free Report) CEO Kevin Mcnamara sold 2,000 shares of the stock in a transaction on Monday, September 28th. The stock was sold at an average price of $513.45, for a total transaction of $1,026,900.00. Following the transaction, the chief executive officer directly owned 66,418 shares in the company, valued at $34,102,322.10. The trade was a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Chemed Stock Performance

CHE stock traded down $6.28 during midday trading on Wednesday, hitting $505.77. 69,772 shares of the company traded hands, compared to its average volume of 207,573. The stock has a market capitalization of $6.61 billion, a price-to-earnings ratio of 25.42, a price-to-earnings-growth ratio of 2.07 and a beta of 0.51. Chemed Corporation has a twelve month low of $365.20 and a twelve month high of $557.00. The company has a quick ratio of 0.89, a current ratio of 0.91 and a debt-to-equity ratio of 0.17. The business has a 50 day simple moving average of $523.47 and a 200-day simple moving average of $460.53.

Chemed (NYSE:CHE - Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 EPS for the quarter, beating analysts' consensus estimates of $5.60 by $0.46. The business had revenue of $673.25 million during the quarter, compared to analyst estimates of $665.04 million. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The firm's revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.27 earnings per share. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. As a group, equities research analysts predict that Chemed Corporation will post 23.55 earnings per share for the current year.

Chemed Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th were paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.6%. This is an increase from Chemed's previous quarterly dividend of $0.60. The ex-dividend date was Monday, August 17th. Chemed's dividend payout ratio is presently 14.06%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Oppenheimer raised their target price on Chemed from $500.00 to $590.00 and gave the company an "outperform" rating in a research note on Friday, July 31st. Weiss Ratings upgraded shares of Chemed from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, July 17th. Bank of America reissued a "neutral" rating on shares of Chemed in a research note on Wednesday, July 29th. Royal Bank Of Canada boosted their target price on Chemed from $436.00 to $548.00 and gave the stock a "sector perform" rating in a research report on Thursday, July 30th. Finally, Wall Street Zen cut shares of Chemed from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 19th. Two investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Chemed presently has a consensus rating of "Hold" and a consensus price target of $554.60.

Institutional Investors Weigh In On Chemed

Institutional investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP acquired a new stake in Chemed in the 2nd quarter valued at $1,726,000. The Manufacturers Life Insurance Company acquired a new stake in Chemed in the 2nd quarter worth about $4,413,000. Lone Peak Global Investors LLC boosted its holdings in Chemed by 38.1% in the 2nd quarter. Lone Peak Global Investors LLC now owns 37,099 shares of the company's stock worth $17,279,000 after buying an additional 10,226 shares during the last quarter. TD Asset Management Inc increased its stake in Chemed by 7.5% during the 4th quarter. TD Asset Management Inc now owns 324,546 shares of the company's stock worth $138,860,000 after buying an additional 22,715 shares in the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of Chemed during the second quarter valued at approximately $9,281,000. Institutional investors and hedge funds own 95.85% of the company's stock.

Chemed Company Profile

Chemed Corporation is a diversified services company headquartered in Cincinnati, Ohio. Its operations are organized through two principal businesses: VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services include clinical care, pain and symptom management, emotional and spiritual support, and assistance for patients and their families in homes, hospice residences, hospitals, nursing facilities, and other care settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.